Drug-Linker Conjugates for ADC
Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.
The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.
ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.
Drug-Linker Conjugates for ADC Isoform Specific Products
-
Drug-Linker Conjugates for ADC
(327)
View all products
-
Auristatin
(45)
View all products
-
Camptothecins
(33)
View all products
-
Daunorubicins/
Doxorubicins (5)View all products
-
Duocarmycins
(8)
View all products
-
Maytansinoids
(19)
View all products
-
Pyrrolobenzodiazepines
(5)
View all products
-
Traditional Cytotoxic Agents
(31)
View all products
-
Dual payloads
(5)
View all products
All Product Categories
-
Drug-Linker Conjugates for ADC Related Products (500)
Related Products (500)
-
Drug-Linker Conjugates for ADC Isoform Comparison
-
LP-6
0 ImagesCat. No.: HY-157079CAS No.: 1629736-79-3LP-6 is a Drug-Linker Conjugate for ADC, and can be used for synthesis of ADCs. LP-6 consists of an Eg5 inhibitor and a linker.
-
N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan)
0 ImagesCat. No.: HY-177681N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
-
Paclitaxel-MVCP
0 ImagesCat. No.: HY-177146CAS No.: 2119034-12-5Synonyms: MC-Val-Cit-PAB-PaclitaxelPaclitaxel-MVCP (MC-Val-Cit-PAB-Paclitaxel) is a MC-Val-Cit-PAB (HY-78738) and Paclitaxel (HY-B0015) conjugate, and can be used for synthesis of Paclitaxel-nucleolin aptamer conjugate.
-
MC-Val-Cit-PAB-clindamycin
0 ImagesMC-Val-Cit-PAB-clindamycin is a agent-linker conjugate for ADC with potent antitumor activity by using clindamycin (a protein synthesis inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
-
DL-01 TFA
0 ImagesCat. No.: HY-155870BDL-01 TFA is the TFA salt form of DL-01 (HY-155870). DL-01 TFA is a drug-linker conjugates for ADC that can be used for the synthesis of ADCs.
-
MA-PEG4-VC-PAB-DMEA-duocarmycin DM TFA
0 ImagesCat. No.: HY-157465AMA-PEG4-VC-PAB-DMEA-duocarmycin DM TFA is a drug-linker conjugate for ADC by using the DNA minor-groove alkylator Duocarmycin DM (HY-130978), linked via MA-PEG4-vc-PAB-DMEA (HY-126668).
-
Lys-Nε-SPDB-DM4
0 ImagesLys-Nε-SPDB-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Lys-Nε-SPDB to make antibody agent conjugate (ADC).
-
Aminobenzenesulfonic auristatin E
0 ImagesCat. No.: HY-145989CAS No.: 1800462-99-0Aminobenzenesulfonic auristatin E is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic.
-
Aniline-PEG3-C1-Boc
0 ImagesCat. No.: HY-164637CAS No.: 2115897-27-1Aniline-PEG3-C1-Boc (compound D-1) is an intermediate of cytotoxic drug linker polymer. Aniline-PEG3-C1-Boc can be used in the synthesis of antibody-drug conjugates (ADCs).
-
Fmoc-Val-Cit-PAB-MMAF-OtBu
0 ImagesCat. No.: HY-204602CAS No.: 863971-54-4Fmoc-Val-Cit-PAB-MMAF-OtBu is a conjugate of MMAF and ADC linker, which can be coupled with the corresponding antibody to form an ADC molecule to exert anti-tumor activity.
-
MC-VC-PAB-Daptomycin
0 ImagesCat. No.: HY-186048CAS No.: 1639428-78-6MC-VC-PAB-Daptomycin (Compound 54) is the linker-payload of an antibody-drug conjugate (ADC). β-Glucuronide-dPBD-PEG6-NH2 is composed of Daptomycin (HY-13631), a lipopeptide antibiotic, and the linker.
-
STING agonist-20-Ala-amide-PEG2-C2-NH2
0 ImagesCat. No.: HY-148346CAS No.: 2720500-49-0STING agonist-20-Ala-amide-PEG2-C2-NH2 is an active scaffold comprising a stimulator of interferon genes (STING). STING agonist-20-Ala-amide-PEG2-C2-NH2 can be used to synthesize immune-stimulating antibody conjugate (ISAC). STING agonist-20-Ala-amide-PEG2-C2-NH2 can be used for the research of cancer.
-
Val-Ala-PAB-SN38
0 ImagesCat. No.: HY-173243CAS No.: 3025787-76-9Val-Ala-PAB-SN38 is a drug-linker conjugate for ADC, composed of ADC linker Val-Ala-PAB (HY-125933) and SN38 (HY-13704), which is the active metabolite of the Topoisomerase I inhibitor Irinotecan (HY-16562).
-
DL-01
0 ImagesCat. No.: HY-155870CAS No.: 2821770-49-2DL-01 is a drug-linker conjugates for ADC that can be used for the synthesis of ADCs.
-
L05-EXd
0 ImagesCat. No.: HY-184561CAS No.: 3128805-51-3L05-EXd is a toxin-linker conjugate, in which the toxin component is Exatecan (HY-13631). L05-EXd can be conjugated with Polatuzumab (HY-P99042) to form the ADC molecule Polatuzumab-L05-EXd. L05-EXd is applicable to research related to small cell lung cancer and non-small cell lung cancer.
-
Ac-RKAA-PABC-MMAE TFA
0 ImagesCat. No.: HY-P11779AAc-RKAA-PABC-MMAE TFA is a Drug-Linker Conjugates for ADC. Ac-RKAA-PABC-MMAE TFA consists of the ADC Cytotoxin MMAE (HY-15162) and a linker. Ac-RKAA-PABC-MMAE TFA can be used for synthesis of ADCs.
-
Mal-Val-Lys-PAB-MMAE TFA
0 ImagesCat. No.: HY-177307APurity: 98.41%Mal-Val-Lys-PAB-MMAE TFA is a drug-linker conjugate for ADC. Mal-Val-Lys-PAB-MMAE TFA consists of a Tubulin inhibitor (MMAE) (HY-15162) and a linker (Mal-Val-Lys-PAB). Mal-Val-Lys-PAB-MMAE TFA can be used for synthesis of ADCs.
-
Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA
0 ImagesCat. No.: HY-126684CAS No.: 2259318-49-3Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA is a agent-linker conjugate for ADC by using the antitumor antibiotic, Duocarmycin SA, linked via Mal-PEG4-VC-PAB-DMEA-Seco.
-
Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE
0 ImagesCat. No.: HY-178219CAS No.: 3103526-19-5Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE contains a linker and bioactive small molecule toxins MMAE (HY-15162). Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE can conjugate with NN2101 (HY-P991293) (anti c-Kit) for synthesizing NN3201. NN3201 rapidly internalizes and inhibits SCF-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models, such as small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST).
-
Ac-RKAA-PABC-MMAE
0 ImagesCat. No.: HY-P11779CAS No.: 2768774-89-4Ac-RKAA-PABC-MMAE is a Drug-Linker Conjugates for ADC. Ac-RKAA-PABC-MMAE consists of the ADC Cytotoxin MMAE (HY-15162) and a linker. Ac-RKAA-PABC-MMAE can be used for synthesis of ADCs.
